A recent study in JAMA Health Forum found that participation in the 340B Drug Pricing Program was associated with a “significant” increase in unprofitable services among public hospitals, but not among nonprofit hospitals. Authors of the study, who are affiliated with two U.S. academic medical centers, analyzed data from approximately 1,000 public and nonprofit hospitals participating in 340B and 1,000 organizations that did not. They concluded the financial proceeds from the drug discounts available through 340B may have helped increase access to services at the public hospitals while nonprofit hospital services remained largely the same, other than an apparent increase in oncology services among participating organizations. https://lnkd.in/dNPTGX5U | #340B #SafetyNet #CriticalAccessHospital #RuralHealth #NonprofitHospital
Kalderos
Data Infrastructure and Analytics
Chicago, IL 5,711 followers
The drug discount platform designed for everyone.
About us
Kalderos delivers technology that solves the challenges facing the US healthcare system. We work with healthcare providers, drug manufacturers, payers, and government agencies alike to increase transparency and restore trust — lowering the cost of healthcare and enabling everyone to focus on improving the health of people.
- Website
-
https://www.kalderos.com/
External link for Kalderos
- Industry
- Data Infrastructure and Analytics
- Company size
- 51-200 employees
- Headquarters
- Chicago, IL
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Technology, Healthcare, Pharmacuticals, 340B Drug Discount Program, Medicaid, Rebates, PBM, Discounts, Drug Pricing, Data Infrastructure, Analytics, MDRP, and CMC
Locations
-
Primary
Get directions
625 W Adams Street
Ste 20-146
Chicago, IL 60661, US
-
Get directions
250 N Sunny Slope Rd
Ste 200
Brookfield, Wisconsin 53005, US
Employees at Kalderos
Updates
-
Our Senior Director of External Affairs and Policy, Gavin Magaha, explains the reasons behind the dysfunctional and unsustainable government drug discount programs in a new article on Drug Channels Institute, an HMP Global Company. In the article, Gavin describes the three key reasons behind the many duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program and then details the state of Oregon’s transparent and collaborative approach, helping eliminate these duplications. #340B #MDRP #DrugDiscountMarket #DuplicateDiscounts #MaximumFairPrice https://lnkd.in/eX3k7QSJ
At the Breaking Point: The Unsustainable Future of Government Drug Discount Programs
drugchannels.net
-
We are thrilled to introduce our newest team members, Nabeeha Ahmed and Ryan Beck! Bee and Ryan bring great enthusiasm and experience to the team, and we're excited to drive progress with them. Welcome to Kalderos! 🎉 #BiasToAction #OneTeam #LeadByExample #DumpsterDivingDataMaven
-
-
🥁🌟 Drumroll, Please! Exciting Announcement!🌟🥁 You're invited to an extraordinary evening of insights and networking with Kalderos and Adam Fein, Ph.D., President of Drug Channels Institute, an HMP Global Company. This exclusive event promises an intimate gathering of industry leaders to discuss pivotal trends in pharmaceuticals and healthcare. 📅 Date: September 24 🕒 Time: 6:00 - 9:00 PM CT 📍 Location: Chicago Architecture Center Highlights include: ➡️In-depth discussions led by Adam J. Fein, Ph.D. focused on government drug discount programs including 340B ➡️Personalized insights into the critical role technology plays in ensuring program sustainability including exploring new innovative models ➡️Elevated ambiance and curated refreshments ⚠️SPACE IS LIMITED⚠️to ensure meaningful interactions and focused discussions. Secure your place now and join us for an evening that promises to inspire and innovate. This event falls during the Informa MDRP conference in Chicago - visit Kalderos at MDRP in addition to our exclusive evening event (walking distance from the MDRP venue) For more details and to reserve your spot, visit: https://lnkd.in/gqb2g-92 Let's shape the future of healthcare together! #ExclusiveEvent #AdamJFein #DrugChannels #Healthcare #Pharmaceuticals #Networking #IndustryInsights
-
-
In several posts on LinkedIn, our board member and distinguished health law attorney, William Sarraille, delivers first-hand reporting and analysis of the 340B Coalition Summer Conference held earlier this month. Bill offers his perspective on the many high-profile speakers and presentations at the conference within the context of multiple lawsuits and reform efforts occurring around the 340B Drug Pricing Program. He also writes about the missed educational opportunities that could have directly benefited patients who rely on those drug discounts to afford their medications. Below is his take on the taped comments from U.S. Rep. Doris Matsui (D-Calif.) who, in March, Social Media Line-Up Prepared For introduced the 340B PATIENTS Act, which Bill writes “would leave a broken 340B program entrenched in its brokenness.” Bill’s post is here: https://lnkd.in/dt29Hhwi #340B #340BReform #340BCoalition #340BHealth #PatientsAct
Nationally Recognized Expert in Health Care and Life Sciences, Educator, Regulatory Consultant, Patient Access Advocate, Independent Director, and Retired Sidley Austin Partner
Rep. #Matsui’s #340B Comments—No Interest in Any Compromise Rep. Matsui, the original co-sponsor of the misleadingly named 340B PATIENTS Act, delivered some taped remarks on the opening day of the 340B Coalition’s Summer Conference. It was part of a “no compromise” stance on legislative reform that was front and center throughout the conference. The Set Up: Matsui’s taped remarks were presented right after Maureen Testoni, 340B Health’s CEO, described, but failed to endorse, the various reform efforts currently underway. There was not even any praise for “Gang of 6” Senate effort, which itself offers a very, very limited reform vision and which, in the vast majority of cases, adopts the CE position on most disputed 340B issues. Testoni signaled support only for Matsui’s bill, which would make all manufacturer contract #pharmacy policies unlawful, even those that only require claims data and otherwise permit an unlimited number of #contractpharmacies. The “PATIENTS” Act would leave a broken 340B program entrenched in its brokenness. There’s no reference in Matsui’s “PATIENTS” Act to: • requiring 340B #hospitals to have any obligation to pass through any discount to needy patients at the pharmacy counter—no matter how extensive their need, • no obligation for those hospitals to at least provide the same level of #charitycare as the average US hospital, or • any requirement for 340B hospitals, which receive almost $43 billion now annually in 340B subsidies, to not subject #patients to crushing #debt collection. In that Vein: Matsui’s comments were very much in the “no compromise” vein of Testoni’s speech and the “PATIENTS” Act. Matsui appeared to equate any call for reform with an “attack” on 340B, citing critics “here in #Congress”—and not just “#bigPhRMA”. Rather than offer even a fig leaf towards #compromise, some modest reform, or even an effort to merely improve the program, Matsui urged stakeholders to just “push back against these attacks”. But what may have been most telling about her no-holds-barred views was her description of contract pharmacy policies. In the face of 2 appellate court cases upholding restrictions as completely consistent with the 340B statute, Matsui dismissed any policy that is employed as merely an effort by #drug makers to “cheat” 340B entities out of discounts. It was red meat to the audience. But we don’t need #pandering. We need #leadership in support of compromises that focus on making the program better for patients at the pharmacy counter. #lifesciences #financialtoxicity #patientaccess #patientsfirst #access #Protect340B #Defende340B #340b #PATIENTSAct
-
The 340B Drug Pricing Program, now exceeding $60 billion in costs, is experiencing exponential growth, systemic waste, misaligned incentives, and an industry plagued by middlemen. These unprecedented challenges are exacerbated by the Inflation Reduction Act and Maximum Fair Price regulations. Our Chief Strategy Officer Daryl Todd will offer insight on how to navigate these uncertain waters during a webinar on Wednesday, August 21, 2024, where he will share how advanced technology can help stakeholders ensure compliance, manage drug discounts efficiently, and restore trust across the complex pharmaceutical landscape. The webinar: “Revolutionizing Government Discount Programs: Why Traditional Methods Fail” will leverage insights from covered entities, policymakers, and industry leaders to propose new compliance models and technology solutions essential for the sustainable future of drug discount programs. REGISTER HERE: https://lnkd.in/df_KB8fk #340B #MedicaidDrugRebateProgram #MDRP #DrugDiscountMarket #InflationReductionAct
-
-
Antonio Papa adds tremendous value to our team, and we are happy to celebrate him in this month's Employee Spotlight! 👏
-
-
Please join us in welcoming Juddson Poeske and Tammy Bugger to Kalderos! We're so excited to have you on the team, and we're looking forward to achieving milestones together! 🚀
-
-
🚨New Article by Gavin Magaha: The Unsustainable Future of Government Drug Discount Programs 🚨 Duplicative claims under 340B and Medicaid Drug Rebate programs are costing billions. The current system needs urgent reform. 🔎 Key Issues: Unsustainable 340B growth. Misaligned incentives and waste. Complexity and high costs due to middlemen. 📢Webinar on August 21, 2024: Revolutionizing Government Discount Programs: Why Traditional Methods Fail. Discover new compliance models and tech solutions. ✅Read & Register: https://lnkd.in/eX3k7QSJ
From Kalderos: At the Breaking Point: The Unsustainable Future of Government Drug Discount Programs Register for 8/21 webinar "Revolutionizing Government Discount Programs: Why Traditional Methods Fail": https://drugch.nl/3S0Z27k Read the article: https://drugch.nl/4cBGKC9 #sponsored
-
-
Kicking off 4th of July with a bang 🎆 We are thrilled to announce our newest Kalderoneans: 🔹 Rose K. Clemons 🔹 Angie Juliana 🔹 Magan Newton, MA, CCSM 🔹 Annie Ortega 🔹 Angelle Horste (she/her/hers) We're eager to learn from their unique experiences, perspectives, and strengths as we drive our mission forward together. Please join us in welcoming them to Team K!
-